Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Authors
Keywords
-
Journal
CNS DRUGS
Volume 37, Issue 1, Pages 45-67
Publisher
Springer Science and Business Media LLC
Online
2022-12-07
DOI
10.1007/s40263-022-00975-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
- (2022) Zihua Zou et al. BMC Medicine
- Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
- (2022) Paul Cottu et al. BREAST
- Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study
- (2022) Rashmi K Murthy et al. CANCER RESEARCH
- Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
- (2022) Joshua K. Sabari et al. CLINICAL CANCER RESEARCH
- Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
- (2022) Steven Sun et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report
- (2022) Fengting Yan et al. Journal of the National Comprehensive Cancer Network
- A multi-centre real-world experience of IMpower150 in oncogene driven tumors and CNS metastases
- (2022) M. Itchins et al. Clinical Lung Cancer
- Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.
- (2022) Joshua K. Sabari et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis
- (2022) Jonathan T. Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
- (2022) Sacha J Howell et al. LANCET ONCOLOGY
- Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
- (2022) Rupert Bartsch et al. NATURE MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
- (2022) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotorasib Shows Intracranial Activity in Patients with <b><i>KRAS G12C-</i></b>Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
- (2022) Kira-Lee Koster et al. Case Reports in Oncology
- Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
- (2021) Neil T. Conlon et al. BRITISH JOURNAL OF CANCER
- Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
- (2021) Hisashi Tanaka et al. Cancer Communications
- Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
- (2021) E. Felip et al. ANNALS OF ONCOLOGY
- Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases
- (2021) Haruka Uezono et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
- (2021) L.A. Emens et al. ANNALS OF ONCOLOGY
- A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging
- (2021) Aki Morikawa et al. BREAST CANCER RESEARCH AND TREATMENT
- Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases
- (2021) Inna Smalley et al. CLINICAL CANCER RESEARCH
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- (2021) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Tissue distribution and brain penetration of niraparib in tumor bearing mouse models and its clinical relevance.
- (2021) Keyur Gada et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.
- (2021) Hamid Emamekhoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.
- (2021) Jennifer Keating Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
- (2021) Erica Michelle Stringer-Reasor et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
- (2021) Ida John et al. JOURNAL OF CLINICAL ONCOLOGY
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small Cell Lung Cancer: A Meta-Analysis
- (2021) Sihan Li et al. Frontiers in Oncology
- The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review
- (2021) PAOLO PALMISCIANO et al. ANTICANCER RESEARCH
- Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
- (2021) Nicholas Turner et al. BREAST CANCER RESEARCH AND TREATMENT
- OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases
- (2021) E. Nadal et al. Journal of Thoracic Oncology
- P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
- (2021) S. Ramalingam et al. Journal of Thoracic Oncology
- Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
- (2021) Hussein A Tawbi et al. LANCET ONCOLOGY
- Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis
- (2021) Barbara Melosky et al. Molecular Diagnosis & Therapy
- Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
- (2021) François Doz et al. NEURO-ONCOLOGY
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
- (2021) Robert Roskoski Jr. PHARMACOLOGICAL RESEARCH
- Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
- (2021) Sanjay M. Prakadan et al. Nature Communications
- Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
- (2021) Priscilla K. Brastianos et al. Nature Communications
- Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report
- (2021) Tyler Lanman et al. Case Reports in Oncology
- Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis
- (2020) Indrawati Hadi et al. Radiation Oncology
- Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
- (2020) Todd M. Bauer et al. Targeted Oncology
- Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
- (2020) Lillian M Smyth et al. CLINICAL CANCER RESEARCH
- Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms.
- (2020) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
- (2020) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
- (2020) Viola W. Zhu et al. Journal of Thoracic Oncology
- Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
- (2020) Priscilla K. Brastianos et al. NATURE MEDICINE
- Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
- (2020) Holger Fischer et al. NEURO-ONCOLOGY
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
- (2020) S. Park et al. ANNALS OF ONCOLOGY
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
- (2020) F. Montemurro et al. ANNALS OF ONCOLOGY
- A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer
- (2020) Sara M Tolaney et al. CLINICAL CANCER RESEARCH
- Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
- (2020) Rachna Malani et al. JOURNAL OF NEURO-ONCOLOGY
- Clinical Trial of Proton Craniospinal Irradiation for Leptomeningeal Metastases
- (2020) T Jonathan Yang et al. NEURO-ONCOLOGY
- The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence
- (2020) Roy Rabbie et al. BRITISH JOURNAL OF CANCER
- Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases:the APOLLO study
- (2020) Ligang Xing et al. CLINICAL CANCER RESEARCH
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
- (2020) Jana Portnow et al. JAMA Oncology
- Treatment strategies for breast cancer brain metastases
- (2020) Caroline Bailleux et al. BRITISH JOURNAL OF CANCER
- Beyond osimertinib: The development of 3rd-generation EGFR Tyrosine Kinase Inhibitors
- (2020) Misako Nagasaka et al. Journal of Thoracic Oncology
- PARP inhibitors coming of age
- (2020) Shani Paluch-Shimon et al. Nature Reviews Clinical Oncology
- Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors
- (2020) Emilie Le Rhun et al. NEURO-ONCOLOGY
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
- (2020) Lisa Mayr et al. Journal of Personalized Medicine
- Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases
- (2019) Elisabeth Sophie Bergen et al. CLINICAL CANCER RESEARCH
- Palliative Radiotherapy for Leptomeningeal Carcinomatosis–Analysis of Outcome, Prognostic Factors, and Symptom Response
- (2019) Rami A. El Shafie et al. Frontiers in Oncology
- Targeting the untargetable KRAS in cancer therapy
- (2019) Pingyu Liu et al. Acta Pharmaceutica Sinica B
- Clinical Management of Adverse Events Associated with Lorlatinib
- (2019) Todd M. Bauer et al. ONCOLOGIST
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- (2019) Rachel A. Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
- (2019) Aki Morikawa et al. CLINICAL CANCER RESEARCH
- A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer
- (2019) Andrea Varrone et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
- (2019) Giuseppe Minniti et al. Journal for ImmunoTherapy of Cancer
- A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
- (2019) An-Chi Tien et al. CLINICAL CANCER RESEARCH
- Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
- (2019) Lizza E.L. Hendriks et al. EUROPEAN JOURNAL OF CANCER
- Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
- (2019) Ronan Flippot et al. JOURNAL OF CLINICAL ONCOLOGY
- Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis
- (2019) Elisabeth Gaye et al. LUNG CANCER
- Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
- (2019) Franziska Maria Ippen et al. NEURO-ONCOLOGY
- Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022
- (2019) Rachel A. Freedman et al. Clinical Breast Cancer
- The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
- (2019) Daniele Presti et al. Cancers
- 333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial
- (2019) P H Cottu et al. ANNALS OF ONCOLOGY
- Management of toxicity to isoform α-specific PI3K inhibitors
- (2019) S E Nunnery et al. ANNALS OF ONCOLOGY
- Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
- (2019) Kourtney Holbrook et al. CANCER
- Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer
- (2019) Emilie Le Rhun et al. NEURO-ONCOLOGY
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report
- (2019) Zhaona Li et al. Thoracic Cancer
- Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials
- (2019) Samantha M. Buszek et al. Frontiers in Oncology
- TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
- (2019) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
- (2019) James C.H. Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
- (2019) Myung-Ju Ahn et al. Journal of Thoracic Oncology
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast cancer brain metastases show increased levels of genomic aberration based homologous recombination deficiency scores relative to their corresponding primary tumors
- (2018) M Diossy et al. ANNALS OF ONCOLOGY
- Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
- (2018) Giuseppina Rosaria Rita Ricciardi et al. BMC CANCER
- LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases
- (2018) Amanda E. D. Van Swearingen et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis
- (2018) Claire Bonneau et al. EUROPEAN JOURNAL OF CANCER
- Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
- (2018) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients
- (2018) Arthur Geraud et al. Journal of Thoracic Oncology
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases
- (2018) Clément Gauvain et al. LUNG CANCER
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Leukaemia hijacks a neural mechanism to invade the central nervous system
- (2018) Hisayuki Yao et al. NATURE
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
- (2018) Haixia Chen et al. Frontiers in Pharmacology
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
- (2018) Shivaani Kummar et al. Targeted Oncology
- Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid
- (2018) Dick Pluim et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis
- (2018) Tamio Okimoto et al. INTERNAL MEDICINE
- Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient
- (2017) Isabella C. Glitza et al. JOURNAL OF NEURO-ONCOLOGY
- High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases
- (2017) Mengxi Ge et al. JOURNAL OF NEURO-ONCOLOGY
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- TRTH-33. COMPARATIVE PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF BRAF AND MEK INHIBITORS IN A NONHUMAN PRIMATE MODEL
- (2017) Louis Rodgers et al. NEURO-ONCOLOGY
- Leptomeningeal melanoma-A case series in the era of modern systemic therapy
- (2017) Malmaruha Arasaratnam et al. Pigment Cell & Melanoma Research
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
- (2017) Thomas Lee Collier et al. Nature Communications
- 456PPRECLINICAL EVIDENCE AND CLINICAL CASES OF AZD9291 ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM)
- (2017) D. Kim et al. ANNALS OF ONCOLOGY
- Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a Review of the Literature
- (2016) Behyar Zoghi et al. Breast Journal
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
- (2016) P. Ballard et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer
- (2016) Shirish M. Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
- (2016) Lucio Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
- (2016) Yang-Si Li et al. Journal of Thoracic Oncology
- Vemurafenib in leptomeningeal carcinomatosis from melanoma
- (2016) Charalampos S. Floudas et al. MELANOMA RESEARCH
- Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report
- (2015) Dae Won Kim et al. BMC CANCER
- Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature
- (2015) Megan O. Jacus et al. CLINICAL PHARMACOKINETICS
- Complete Cytologic Remission of V600E BRAF-Mutant Melanoma–Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib
- (2015) Sofie Wilgenhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
- (2015) Justin F. Gainor et al. Journal of Thoracic Oncology
- Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
- (2015) Javier Cortés et al. LANCET ONCOLOGY
- Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma
- (2015) Lilia Sakji-Dupré et al. MELANOMA RESEARCH
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
- (2015) David M. Jackman et al. Oncotarget
- Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
- (2015) Kimmo J. Hatanpaa et al. NEOPLASIA
- Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases
- (2014) S. Gori et al. ANNALS OF ONCOLOGY
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
- (2014) I. E. Krop et al. ANNALS OF ONCOLOGY
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
- (2014) Puey Ling Chia et al. Clinical Epidemiology
- PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
- (2013) J.-m. Lee et al. ANNALS OF ONCOLOGY
- Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
- (2013) Julio Morales et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Vemurafenib for Leptomeningeal Melanomatosis
- (2013) Niklas Schäfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Investigation of the effect of active efflux at the blood–brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system
- (2013) Mari Miyajima et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer
- (2013) Eunyoung Lee et al. Journal of Thoracic Oncology
- The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer
- (2013) Justin F. Gainor et al. Journal of Thoracic Oncology
- Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib
- (2013) Jee Min Lee et al. MELANOMA RESEARCH
- Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
- (2012) Yosuke Togashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology
- (2011) J. P. Glass et al. NEUROLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
- (2011) Hazem El-Osta et al. PLoS One
- Leptomeningeal metastases in the MRI era
- (2010) J. L. Clarke et al. NEUROLOGY
- Incidence of brain metastases in renal cell carcinoma treated with sorafenib
- (2009) C. Massard et al. ANNALS OF ONCOLOGY
- Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates
- (2009) Jodi A. Muscal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
- (2009) Morris D. Groves et al. JOURNAL OF NEURO-ONCOLOGY
- Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
- (2009) Tatsuya Katayama et al. Journal of Thoracic Oncology
- Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer
- (2008) Deann P. Atchley et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
- (2008) Morris D. Groves et al. NEURO-ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started